Emactuzumab

N/A

Report date: 2025/10/30 13:58:21

Base Information

Drug NameEmactuzumab
Drug Alias Name依米妥珠单抗Emactuzumabum艾马妥组单抗6FY6EI1X8RRG-7155 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionColony stimulating factor 1 receptor inhibitors
TargetsColony stimulating factor 1 receptor
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsHead and Neck Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIngenOx Therapeutics LtdSynOx Therapeutics LtdGenentech Inc
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsProstatic NeoplasmsHead and Neck NeoplasmsCarcinoma, Squamous Cell +[5] 
Inactive IndicationsSolid tumoursLymphoma, Non-HodgkinNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia